Full-Time

Manufacturing Science and Technology Engineer

Abzena

Abzena

201-500 employees

CDMO for complex biologics and ADCs

No salary listed

Bristol, PA, USA

In Person

On-site role; no remote work.

Category
Biology & Biotech (1)

Get referred to Abzena

See people who can refer or advise you

Requirements
  • Bachelor’s degree in scientific or engineering discipline or equivalent with 3-5 years of experience in biopharma MSAT or technical operations with a focus on ADC and/or AOC processes
  • Proven track record in both development and clinical-stage support, including batch record authorship and process documentation
  • Working knowledge of GMP operations, including manufacturing floor support, deviation resolution, and change control
  • Hands-on experience with conjugation chemistries, tangential flow filtration (TFF), Protein A, ion exchange (IEX), and hydrophobic interaction chromatography (HIC)
  • Strong understanding of Microsoft Office Suite including basic functions and graphing within Microsoft Excel
  • Familiarity with semi/fully automated manufacturing equipment
  • Proven ability to troubleshoot bioprocess operations and equipment
  • Understanding of relevant analytical, processing, and scale-up calculations
  • Proven ability to build, modify, and utilize digital data storage, visualization, and analysis systems/tools
  • Strong interpersonal and communication skills, with the ability to interface effectively with cross-functional teams and clients
Responsibilities
  • Provide technical leadership for technology transfer from internal or external process development teams into cGMP manufacturing, including facility fit assessments, scale up planning, and risk assessments
  • Lead transfer of bioconjugation processes into cGMP manufacturing from internal teams and external development partners
  • Author and revise batch records and master batch production documents to support cGMP clinical manufacturing
  • Draft and maintain cGMP documentation, including BOMs, specifications, SOPs, technology transfer documents, PFDs, and P&IDs, as required to support execution and readiness
  • Lead or support process investigations, deviations, CAPAs, and root cause analysis related to cGMP manufacturing
  • Champion process safety by translating OEB controls into practical manufacturing requirements for equipment, PPE, waste, and cleaning
  • Provide in-person and real-time manufacturing production support required for project success
  • Drive continuous improvement initiatives related to process robustness, documentation, and manufacturing efficiency
  • Technical training and knowledge management. Develop training content for new processes, new equipment, and new batch record revisions. Maintain a living knowledge package per program, including lessons learned, known failure modes, and standard responses
  • Adhere to all GLP, and cGMP requirements as well as Abzena policies, procedures, and mission while fulfilling duties, responsibilities, and tasks
  • Serve as the MSAT subject matter expert (SME) for bioconjugation processes including ADCs and AOCs across early development through commercial lifecycle stages

Abzena is a CDMO that provides integrated services for complex biologics and bioconjugates, including antibody-drug conjugates (ADCs). It supports projects from antibody discovery through GMP manufacturing for clinical trials and commercial supply, using its in-house platforms and expertise. It differentiates itself with end-to-end development and manufacturing capabilities, supported by proprietary technologies like ThioBridge and Composite Human Antibody, and global facilities in San Diego, Bristol, and Cambridge. Its goal is to help biologics programs progress efficiently from discovery to market by offering specialized, partnered development and manufacturing services and potential licensing of its technologies.

Company Size

201-500

Company Stage

IPO

Headquarters

Babraham, United Kingdom

Founded

2001

Get referred to Abzena

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growing demand for end-to-end biologics outsourcing supports integrated program wins.
  • Multi-site footprint in San Diego, Bristol, and Cambridge expands geographic reach.
  • Analytical and immunogenicity capabilities help de-risk complex programs earlier.

What critics are saying

  • Bioconjugate platform commoditization erodes differentiation and pricing power.
  • Clients can unbundle services, shrinking margins on integrated projects.
  • Heavy reliance on program wins exposes revenue to customer insourcing and vendor consolidation.

What makes Abzena unique

  • Integrated CDMO+CRO spans discovery through GMP manufacturing for complex biologics.
  • Specialized bioconjugation covers ADCs, AOCs, RDCs, linker-payloads, and polymers.
  • Proprietary platforms include ThioBridge® and Composite Human Antibody™.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Abzena
Mar 17th, 2026
Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations.

Frost radar report: Antibody-Drug Conjugate contract development & manufacturing organizations. Abzena is recognized as a technology-forward, innovative CDMO in the Frost radar(tm): ADC contract development and manufacturing report, 2025. In this comprehensive analysis of the Antibody-Drug Conjugate (ADC) contract development and manufacturing (CDMO) market, global research analysts Frost & Sullivan, an independent firm, evaluated leading service providers and recognized Abzena as a Leader in both Innovation and Growth. As the author of the report, Unmesh Lal, VP of Healthcare & Life Sciences at Frost & Sullivan, shared, "With deep analytical expertise, flexible licensing models, and a dual US-UK footprint, Abzena combines scientific rigor with commercial agility. Its 'grow-with-the-client' strategy is converting early-stage partnerships into long-term manufacturing relationships, solidifying its position as a premier end-to-end CDMO for complex biologics." * How Abzena's proprietary ThioBridge(R) site-specific conjugation platform improves the design & delivery of ADCs. * How a fully integrated end-to-end development and manufacturing model eliminates tech-transfer risks and reduces timelines & costs. * How assay development for complex ADC & AOC characterization provides the data needed to de-risk clinical programs & build confidence with regulators and investors * How a dual US and UK integrated footprint provides a secure supply chain and deep FDA and EMA regulatory expertise.

Clinical Research News
Sep 16th, 2025
Abzena Enhances AbZelectPRO(TM) Cell Line Offering with New GS Knockout Platforms

Abzena enhances abzelectpro(tm) cell line offering with new GS knockout platforms san diego, CA - september 15, 2025 - abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its abzelectpro(tm) cell line development (CLD) platform with the launch of two next-generation glutamine synthetase ("GS") knockout CHO-K1 expression systems, including a double knockout ADCC+ platform for afucosylated proteins.

Bio-IT World
Jul 22nd, 2025
Appointment; Abzena Appoints Geoffrey M. Glass as Chief Executive Officer

San Diego, CA - July 22, 2025 - Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, today announced that Geoffrey M. Glass has been appointed Chief Executive Officer (CEO), effective immediately.

PR Newswire
May 15th, 2025
Abzena Announces Establishment Of Scientific Advisory Board To Support Innovation Strategy

SAN DIEGO, May 15, 2025 /PRNewswire/ -- Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today the formation of its Scientific Advisory Board (SAB) comprised of biopharma industry experts with diversified expertise in Discovery Research & Development (R&D) and Chemistry, Manufacturing, and Controls (CMC). The new advisory board will work closely with Abzena's scientific and commercial leadership to provide strategic guidance and expert insights that support Abzena's continued commitment to growth and innovation.Matt Stober, CEO of Abzena, said, "The establishment of the Scientific Advisory Board was a strategic decision to help guide the future of Abzena. We have seen considerable momentum over the past few years in supporting complex and innovative modalities, such as Antibody-drug conjugates (ADCs), Antibody-oligonucleotide conjugates (AOCs), and bispecifics. We aim to continue building upon this by offering the most state-of-the-art technologies and capabilities to support our customers' programs. These experts will be instrumental in assisting us with this mission by evaluating our strategies and providing recommendations that will further enhance our ability to move medicines forward to patients faster."Joe Principe, CCO of Abzena, said, "We are honored to welcome these distinguished individuals to our Scientific Advisory Board. These founding members are recognized leaders in our industry, bringing a wealth of expertise that will help guide us as we continue through this significant phase of our growth

Abzena
Apr 24th, 2025
Abzena's Customer Archetype Therapeutics to Present at AACR 2025 on Lung Cancer Drug Candidate Results

Archetype is partnering with contract research organizations (CROs) Abzena and Alloy Therapeutics, to design and develop Antibody-drug conjugates (ADCs) using some of the clinical stage and approved targeted therapy small molecules featured in the presentation.